Medicine reference
Melanotan I (Afamelanotide)
A source-linked medicine reference on Melanotan I (Afamelanotide), its documented context and safety boundaries. Sources checked 6 September 2026.
Source and review status
Published sources checked
Sources checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 March 2027.
Identity and scope
Afamelanotide is the active substance in Scenesse, an EMA product for erythropoietic protoporphyria; it should not be treated as equivalent to unregulated “Melanotan” tanning powder sold online.
Sources: European Medicines Agency
Documented context
The cited EMA material describes a specific medicine and EPP context. This page does not claim that a tanning product is safe, equivalent, or suitable for cosmetic tanning.
Sources: European Medicines Agency
Safety and a useful record
Product identity and regulated supply are material. A name similarity is not evidence of composition, quality or clinical indication.
Sources: European Medicines Agency
Record the exact product and regulatory information, rather than using “Melanotan I” as a catch-all name.
Published sources
- Scenesse (afamelanotide) EPAR
European Medicines Agency. Current EMA product information; accessed 6 September 2026.
Supports: Afamelanotide/Scenesse identity and EPP medicine context; not online tanning products.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Source-linked reference published | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.